AR-V7 Biomarker Test Remains on the Wish List for CRPC

Ariela Katz
Published: Sunday, Aug 20, 2017
William Oh, MD
William Oh, MD
The use of biomarkers in genitourinary cancers offers exciting potential in understanding which patients may do better with androgen-targeting therapies. Progress in developing biomarker tests is frustratingly slow, according to William K. Oh, MD.

“If AR-V7 testing became more widely available, which it may later this year, then maybe patients who have high levels of AR-V7 would be better candidates for chemotherapy instead of an androgen receptor-targeted treatment,” Oh said.
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-1038. doi:10.1056/NEJMoa1315815.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication